Filing Flows › Zenas BioPharma (ZBIO) › Q3 2026
Zenas BioPharma (ZBIO) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Zenas BioPharma (ZBIO) reported revenue of $10.0M for the third quarter 2026 (Q3 2026) and +900% from the quarter before.
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.0M | +900% | — |
| Operating profit | −$103M | — | — |
| Net earnings | −$109M | — | — |
| Operating cash flow | −$58.0M | — | — |
What changed
Revenue was $10.0M in Q3 2026, up 900% from the previous quarter.
Operating costs exceeded revenue by $103.4M, an operating margin of -1034.1%. The quarter ended with a net loss of $108.9M, narrower than the previous quarter's $111.5M loss.
Operating cash flow was −$58.0M. Non-cash charges added back $4K of depreciation and $17.3M of share-based compensation. Working capital and other items added $33.7M. Capital expenditures of $1K exceeded it, leaving free cash flow of −$58.0M.
Questions
What was Zenas BioPharma's revenue in the third quarter 2026?
Zenas BioPharma (ZBIO) reported revenue of $10.0M for the third quarter 2026 (Q3 2026) and +900% from the quarter before.
Source: Zenas BioPharma 10-Q on SEC EDGAR.